Arcturus Therapeutics (ARCT) Tops Q1 EPS by 338c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.94, $3.38 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $5.24 million versus the consensus estimate of $6.3 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance